Prestige Consumer Healthcare (PBH) Stock Forecast, Price Target & Predictions
PBH Stock Forecast
Prestige Consumer Healthcare stock forecast is as follows: an average price target of $89.50 (represents a 13.69% upside from PBH’s last price of $78.72) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PBH Price Target
The average price target for Prestige Consumer Healthcare (PBH) is $89.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $93.00 to $86.00. This represents a potential 13.69% upside from PBH's last price of $78.72.
PBH Analyst Ratings
According to 3 Wall Street analysts, Prestige Consumer Healthcare's rating consensus is 'Buy'. The analyst rating breakdown for PBH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Prestige Consumer Healthcare Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | SUsan Anderson | Canaccord Genuity | $86.00 | $74.58 | 15.32% | 9.25% |
| Jun 21, 2024 | Linda Bolton Weiser | D.A. Davidson | $93.00 | $68.13 | 36.51% | 18.14% |
| Nov 17, 2022 | Canaccord Genuity | $71.00 | $58.35 | 21.68% | -9.81% |
The latest Prestige Consumer Healthcare stock forecast, released on Nov 05, 2024 by SUsan Anderson from Canaccord Genuity, set a price target of $86.00, which represents a 15.32% increase from the stock price at the time of the forecast ($74.58), and a 9.25% increase from PBH last price ($78.72).
Prestige Consumer Healthcare Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $86.00 | $89.50 |
| Last Closing Price | $78.72 | $78.72 | $78.72 |
| Upside/Downside | -100.00% | 9.25% | 13.69% |
In the current month, the average price target of Prestige Consumer Healthcare stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prestige Consumer Healthcare's last price of $78.72. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 05, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 23, 2024 | Jefferies | Buy | Hold | Downgrade |
| Nov 17, 2022 | Canaccord Genuity | Buy | Initialise | |
| May 10, 2022 | Jefferies | Buy | Upgrade | |
| May 09, 2022 | Oppenheimer | Outperform | Upgrade |
Prestige Consumer Healthcare's last stock rating was published by Canaccord Genuity on Nov 05, 2024. The company gave PBH a "Buy" rating, the same as its previous rate.
Prestige Consumer Healthcare Financial Forecast
Prestige Consumer Healthcare Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $282.74M | $286.32M | $279.31M | $285.87M | $275.52M | $289.27M | $277.06M | $266.94M | $274.47M | $276.23M | $269.18M | $237.76M | $238.79M | $237.42M | $229.39M | $251.24M | $241.55M |
| Avg Forecast | $299.40M | $294.20M | $292.40M | $277.90M | $297.20M | $291.15M | $290.12M | $277.88M | $294.60M | $287.07M | $282.09M | $260.42M | $287.42M | $280.25M | $285.22M | $278.79M | $278.92M | $273.84M | $283.20M | $268.92M | $258.25M | $260.37M | $261.23M | $232.41M | $230.59M | $231.55M | $227.43M | $221.27M | $239.65M | $240.52M |
| High Forecast | $303.78M | $298.50M | $296.67M | $281.96M | $301.55M | $295.41M | $294.36M | $281.94M | $297.82M | $287.19M | $282.15M | $260.48M | $287.42M | $284.34M | $285.41M | $282.86M | $282.99M | $277.84M | $283.20M | $268.92M | $258.25M | $260.37M | $261.23M | $232.41M | $230.59M | $231.55M | $227.43M | $221.27M | $239.65M | $240.52M |
| Low Forecast | $294.10M | $288.99M | $287.22M | $272.98M | $291.94M | $286.00M | $284.99M | $272.96M | $291.94M | $286.97M | $282.04M | $260.36M | $287.42M | $275.29M | $285.09M | $273.85M | $273.98M | $268.99M | $283.20M | $268.92M | $258.25M | $260.37M | $261.23M | $232.41M | $230.59M | $231.55M | $227.43M | $221.27M | $239.65M | $240.52M |
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 6 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 1.00% | 1.02% | 1.01% | 1.02% | 1.03% | 1.03% | 1.05% | 1.06% | 1.16% | 1.03% | 1.03% | 1.04% | 1.04% | 1.05% | 1.00% |
Prestige Consumer Healthcare's average Quarter revenue forecast for Mar 24 based on 2 analysts is $287.42M, with a low forecast of $287.42M, and a high forecast of $287.42M. PBH's average Quarter revenue forecast represents a 1.66% increase compared to the company's last Quarter revenue of $282.74M (Dec 23).
Prestige Consumer Healthcare EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 6 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $91.79M | $93.69M | $91.99M | $95.68M | $94.16M | $91.82M | $94.57M | $83.63M | $90.47M | $83.91M | $99.04M | $66.89M | $81.42M | $80.71M | $87.60M | $80.34M | $82.45M |
| Avg Forecast | $79.96M | $78.57M | $78.09M | $74.22M | $79.37M | $77.76M | $77.48M | $74.21M | $78.68M | $76.67M | $75.34M | $69.55M | $101.04M | $74.85M | $76.17M | $74.46M | $91.85M | $87.07M | $95.08M | $90.29M | $83.50M | $87.42M | $87.71M | $78.03M | $66.04M | $77.74M | $76.36M | $74.29M | $71.65M | $80.75M |
| High Forecast | $81.13M | $79.72M | $79.23M | $75.30M | $80.53M | $78.89M | $78.62M | $75.30M | $79.54M | $76.70M | $75.35M | $69.57M | $121.25M | $75.94M | $76.22M | $75.54M | $110.22M | $104.49M | $95.08M | $90.29M | $100.20M | $87.42M | $87.71M | $78.03M | $79.24M | $77.74M | $76.36M | $74.29M | $85.99M | $80.75M |
| Low Forecast | $78.54M | $77.18M | $76.71M | $72.90M | $77.97M | $76.38M | $76.11M | $72.90M | $77.97M | $76.64M | $75.32M | $69.53M | $80.83M | $73.52M | $76.14M | $73.14M | $73.48M | $69.66M | $95.08M | $90.29M | $66.80M | $87.42M | $87.71M | $78.03M | $52.83M | $77.74M | $76.36M | $74.29M | $57.32M | $80.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.23% | 1.23% | 1.24% | 1.04% | 1.08% | 0.97% | 1.05% | 1.00% | 1.03% | 0.96% | 1.27% | 1.01% | 1.05% | 1.06% | 1.18% | 1.12% | 1.02% |
2 analysts predict PBH's average Quarter EBITDA for Mar 24 to be $101.04M, with a high of $121.25M and a low of $80.83M. This is 10.08% upper than Prestige Consumer Healthcare's previous annual EBITDA (Dec 23) of $91.79M.
Prestige Consumer Healthcare Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 6 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $53.05M | $53.56M | $53.28M | $-240.55M | $51.95M | $51.02M | $55.27M | $52.09M | $50.22M | $45.33M | $57.76M | $35.51M | $40.87M | $44.59M | $43.71M | $37.05M | $38.06M |
| Avg Forecast | $69.00M | $66.50M | $62.00M | $57.00M | $65.31M | $62.20M | $59.53M | $53.60M | $64.77M | $57.91M | $54.23M | $42.97M | $61.61M | $52.04M | $53.36M | $50.47M | $56.01M | $48.33M | $50.35M | $52.19M | $50.92M | $44.40M | $49.60M | $43.56M | $35.06M | $38.56M | $36.05M | $35.19M | $33.04M | $37.70M |
| High Forecast | $70.31M | $67.76M | $63.18M | $58.08M | $66.55M | $63.38M | $60.66M | $54.62M | $66.28M | $59.01M | $54.29M | $42.98M | $73.93M | $53.03M | $54.37M | $51.43M | $67.21M | $58.00M | $50.35M | $52.19M | $61.10M | $44.40M | $49.60M | $43.56M | $42.07M | $38.56M | $36.05M | $35.19M | $39.65M | $37.70M |
| Low Forecast | $67.41M | $64.97M | $60.57M | $55.69M | $63.81M | $60.77M | $58.16M | $52.37M | $64.27M | $56.58M | $54.16M | $42.96M | $49.29M | $50.84M | $52.13M | $49.31M | $44.81M | $38.67M | $50.35M | $52.19M | $40.73M | $44.40M | $49.60M | $43.56M | $28.05M | $38.56M | $36.05M | $35.19M | $26.43M | $37.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.00% | 1.06% | -4.30% | 1.07% | 1.01% | 1.06% | 1.02% | 1.13% | 0.91% | 1.33% | 1.01% | 1.06% | 1.24% | 1.24% | 1.12% | 1.01% |
Prestige Consumer Healthcare's average Quarter net income forecast for Mar 24 is $61.61M, with a range of $49.29M to $73.93M. PBH's average Quarter net income forecast represents a 16.14% increase compared to the company's last Quarter net income of $53.05M (Dec 23).
Prestige Consumer Healthcare SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 6 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $65.47M | $66.10M | $63.92M | $58.53M | $56.96M | $70.26M | $66.67M | $64.75M | $66.22M | $72.98M | $61.91M | $60.24M | $59.48M | $58.73M | $47.68M | $63.75M | $54.87M |
| Avg Forecast | $70.90M | $69.67M | $69.25M | $65.81M | $70.38M | $68.95M | $68.71M | $65.81M | $69.77M | $67.98M | $66.81M | $61.67M | $76.58M | $66.37M | $67.54M | $66.02M | $69.62M | $63.74M | $67.07M | $63.69M | $63.29M | $61.66M | $61.86M | $55.04M | $59.47M | $54.83M | $53.86M | $52.40M | $56.86M | $56.96M |
| High Forecast | $71.94M | $70.69M | $70.26M | $66.77M | $71.41M | $69.96M | $69.71M | $66.77M | $70.53M | $68.01M | $66.82M | $61.69M | $91.90M | $67.34M | $67.59M | $66.99M | $83.54M | $76.49M | $67.07M | $63.69M | $75.95M | $61.66M | $61.86M | $55.04M | $71.36M | $54.83M | $53.86M | $52.40M | $68.23M | $56.96M |
| Low Forecast | $69.65M | $68.44M | $68.02M | $64.65M | $69.14M | $67.73M | $67.49M | $64.64M | $69.14M | $67.96M | $66.79M | $61.66M | $61.26M | $65.19M | $67.51M | $64.85M | $55.70M | $50.99M | $67.07M | $63.69M | $50.63M | $61.66M | $61.86M | $55.04M | $47.57M | $54.83M | $53.86M | $52.40M | $45.49M | $56.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 0.98% | 0.97% | 0.84% | 0.89% | 1.05% | 1.05% | 1.02% | 1.07% | 1.18% | 1.12% | 1.01% | 1.08% | 1.09% | 0.91% | 1.12% | 0.96% |
Prestige Consumer Healthcare's average Quarter SG&A projection for Mar 24 is $76.58M, based on 2 Wall Street analysts, with a range of $61.26M to $91.90M. The forecast indicates a 16.97% rise compared to PBH last annual SG&A of $65.47M (Dec 23).
Prestige Consumer Healthcare EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 6 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 9 | 9 | 9 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.07 | $1.08 | $1.07 | $-4.83 | $1.05 | $1.02 | $1.10 | $1.03 | $1.00 | $0.90 | $1.15 | $0.71 | $0.81 | $0.89 | $0.87 | $0.74 | $0.76 |
| Avg Forecast | $1.38 | $1.33 | $1.24 | $1.14 | $1.31 | $1.24 | $1.19 | $1.07 | $1.30 | $1.16 | $1.08 | $0.86 | $1.14 | $1.04 | $1.07 | $1.01 | $1.04 | $1.01 | $1.00 | $1.04 | $0.89 | $0.88 | $0.99 | $0.87 | $0.78 | $0.77 | $0.72 | $0.70 | $0.74 | $0.75 |
| High Forecast | $1.41 | $1.36 | $1.26 | $1.16 | $1.33 | $1.27 | $1.21 | $1.09 | $1.33 | $1.18 | $1.09 | $0.86 | $1.14 | $1.06 | $1.09 | $1.03 | $1.06 | $1.03 | $1.00 | $1.04 | $0.89 | $0.88 | $0.99 | $0.87 | $0.78 | $0.77 | $0.72 | $0.70 | $0.74 | $0.75 |
| Low Forecast | $1.35 | $1.30 | $1.21 | $1.11 | $1.28 | $1.22 | $1.16 | $1.05 | $1.29 | $1.13 | $1.08 | $0.86 | $1.14 | $1.02 | $1.04 | $0.99 | $1.02 | $0.99 | $1.00 | $1.04 | $0.89 | $0.88 | $0.99 | $0.87 | $0.78 | $0.77 | $0.72 | $0.70 | $0.74 | $0.75 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.01% | 1.06% | -4.65% | 1.04% | 1.02% | 1.06% | 1.16% | 1.13% | 0.91% | 1.33% | 0.91% | 1.06% | 1.24% | 1.24% | 1.01% | 1.01% |
According to 2 Wall Street analysts, Prestige Consumer Healthcare's projected average Quarter EPS for Mar 24 is $1.14, with a low estimate of $1.14 and a high estimate of $1.14. This represents a 6.46% increase compared to PBH previous annual EPS of $1.07 (Dec 23).
Prestige Consumer Healthcare Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EVO | Evotec SE | $4.78 | $8.00 | 67.36% | Buy |
| AMPH | Amphastar Pharmaceuticals | $40.85 | $66.00 | 61.57% | Buy |
| ANIP | ANI Pharmaceuticals | $55.83 | $79.00 | 41.50% | Buy |
| COLL | Collegium Pharmaceutical | $30.90 | $42.33 | 36.99% | Buy |
| PCRX | Pacira BioSciences | $19.83 | $23.75 | 19.77% | Hold |
| PBH | Prestige Consumer Healthcare | $80.39 | $89.50 | 11.33% | Buy |
| SUPN | Supernus Pharmaceuticals | $36.22 | $36.00 | -0.61% | Buy |
| PAHC | Phibro Animal Health | $22.34 | $18.67 | -16.43% | Buy |